Polymer Gel Sustained Release of Natriuretic Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering natriuretic polypeptides to treat heart failure and related conditions are limited by the short half-life of these peptides, requiring frequent hospitalizations and high re-admission and mortality rates, with chronic administration outside the hospital setting being challenging due to subcutaneous bolus administration.
Innovation Solution
Development of polymer gel compositions containing natriuretic polypeptides, such as CD-NP, using polymers like poly(lactic-co-glycolic acid) and solvents like N-methyl-2-pyrrolidinone, which protect the peptides from degradation and release them therapeutically over weeks to months, allowing for sustained delivery in a non-clinical setting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If natriuretic polypeptides are administered via subcutaneous bolus injection, then the treatment can be given in a non-clinical setting, but the short half-life requires frequent administration and results in high re-admission and mortality rates
Solution Approach 1:
A polymer gel composition acts as an intermediary carrier system that encapsulates natriuretic polypeptides, enabling sustained release over weeks to months. The gel matrix serves as a reservoir that gradually releases the therapeutic peptide, eliminating the need for frequent injections while maintaining therapeutic levels in the bloodstream
Solution Approach 2:
The invention changes the physical and chemical parameters of the natriuretic polypeptide delivery system by formulating it within a polymer gel matrix. This transformation from direct injection to gel-encapsulated delivery fundamentally alters the release kinetics, extending the duration of action from hours to months while maintaining ease of administration
2Reliability
If natriuretic polypeptides are administered intravenously during hospitalization, then therapeutic levels are achieved, but frequent hospitalizations are required and re-admission rates remain high
Solution Approach 1:
The polymer gel composition is prepared in advance with the natriuretic polypeptide encapsulated within its matrix. This preliminary formulation allows the therapeutic to be administered as a single injection that continuously releases the peptide over weeks to months, eliminating the need for repeated hospital visits and intravenous administrations
3Reliability
If the half-life of natriuretic polypeptides is extended through frequent administration, then therapeutic levels are maintained, but the complexity of administration increases and patient compliance decreases
Solution Approach 1:
The polymer gel composition provides continuous release of natriuretic polypeptides over an extended period, maintaining therapeutic levels without interruption. This continuous action is achieved through the gradual degradation and release mechanism of the gel matrix, eliminating the need for multiple discrete administration events
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer gel compositions effectively maintain therapeutic levels of natriuretic polypeptides in circulation for extended periods, reducing the need for frequent administration and improving treatment outcomes for conditions like heart failure, cardiovascular disease, and hypertension.
Implementation Method 1
polymer gel compositions containing NPs can be designed to include one or more NPs at a concentration and in an environment that (a) protects the NPs from degradation over a period of time
Implementation Method 2
releases therapeutic levels of the NPs from the composition into the mammal's circulation over a period of time
Data Source
AI summary
This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided.